文献速递乳腺外科

乳腺癌新辅助化疗后残留病灶中干细胞样细胞的分子分析

Surgical resection of breast cancers: Molecular analysis of cancer stem cells in residual disease.
PubMed 文献 · Surgery · 2019-02-15

该研究纳入68例乳腺癌标本(44例初治、24例新辅助化疗后残留),用流式分选鉴定干细胞样乳腺癌细胞并检测PIK3CA突变。结果发现残留病灶中仍存在PIK3CA突变的干细胞样细胞,提示新辅助化疗未完全清除这类细胞,可能解释残留病灶预后不良。

要点

  • 新辅助化疗后残留病灶中仍可检测到PIK3CA突变的干细胞样乳腺癌细胞。
  • CD49f-CD24+干细胞样细胞中PIK3CA突变频率最高(初治39%、残留33%)。
  • PIK3CA突变见于各期乳腺癌(35%),初治39%、残留29%,ER阳性41%、阴性14%(P=ns)。

核心结论

  • 新辅助化疗不能完全清除PIK3CA突变的干细胞样乳腺癌细胞,残留病灶中仍存在这类细胞。

研究设计与样本

  • 收集68例乳腺癌标本,其中44例为化疗初治、24例为新辅助化疗后残留病灶。
  • 用荧光激活细胞分选术结合乳腺干细胞相关抗体鉴定干细胞样乳腺癌细胞,并对全肿瘤标本及分选细胞进行基因突变分析(包括PIK3CA)。

主要发现

  • 干细胞样乳腺癌细胞(EpCAM阳性、CD44阳性、CD49f±、CD24±)存在于化疗初治肿瘤和残留病灶中。
  • 初治和残留病灶中,CD49f-CD24+干细胞样乳腺癌细胞的PIK3CA突变频率最高(分别为39%和33%)。
  • PIK3CA突变见于所有分期乳腺癌(35%),初治39%、残留29%,雌激素受体阳性41%、阴性14%(P=ns)。
  • 在配对和非配对乳腺癌中,初治标本与残留病灶标本可检测到不同的PIK3CA突变。

临床怎么用

  • 残留病灶中PIK3CA突变的干细胞样细胞可能成为治疗靶点,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 70% of breast cancer patients have residual disease after neoadjuvant chemotherapy. This study was designed to determine whether breast cancer cells with stemlike properties are present in residual disease after neoadjuvant chemotherapy and whether they exhibit oncogenic mutations. The presence of breast cancer cells with stemlike properties with specific mutations may help explain the poor prognosis associated with residual disease. METHODS: A total of 68 breast cancer specimens were collected at the time of mastectomy or lumpectomy. A total of 44 were chemotherapy naïve and 24 were collected as residual disease after neoadjuvant chemotherapy. Tumor cells were collected by fluorescence-activated cell sorting, with breast cancer cells with stemlike properties specifically identified using breast stem cell associated antibodies. Whole tumor specimens and fluorescence-activated cell sorting breast cancer cells with stemlike properties were analyzed for genetic mutations, including PIK3CA. RESULTS: Breast cancer cells with stemlike properties, demonstrating EpCAM-positive, CD44-positive, CD49f±, CD24± expression were present in chemotherapy-naïve tumors and residual disease. In both chemotherapy-naïve and residual disease specimens the highest frequency of PIK3CA mutations were detected in CD49f-CD24+ BCSCs (39% and 33%, respectively). PIK3CA mutations were detected in all stages of breast cancer (35%), in both chemotherapy naïve (39%) and residual disease (29%) and in both estrogen receptor positive (41%) and negative tumors (14%) (P = ns). Various PIK3CA mutations were identified in chemotherapy-naïve specimens versus residual disease specimens in both patient-paired and unpaired breast cancers. CONCLUSION: Breast cancer cells with stemlike properties with mutations in PIK3CA were present in chemotherapy-naïve breast cancers and residual disease after neoadjuvant chemotherapy. These results demonstrate that neoadjuvant chemotherapy does not completely eradicate PIK3CA-defective breast cancer cells with stemlike properties. Although these findings may help explain the poor clinical outcomes in patients with residual disease, they also identify breast cancer cells with stemlike-property targets for therapies.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Pommier SJ, Morgan RE, Limbach KE, et al. Surgical resection of breast cancers: Molecular analysis of cancer stem cells in residual disease. Surgery. 2019. PMID: 30777364. doi:10.1016/j.surg.2019.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。